Literature DB >> 16126457

Ivermectin 20 years on: maturation of a wonder drug.

Timothy G Geary1.   

Abstract

Ivermectin has been on the veterinary market for almost a quarter of a century and has been approved for human use for 18 years. Its use has revolutionized the treatment of nematode and arthropod parasites in animals and has provided hope for the control or even eradication of filariases in humans. Although much remains to be learned about how the drug works and how resistance to it will develop, it has earned the title of "wonder drug".

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16126457     DOI: 10.1016/j.pt.2005.08.014

Source DB:  PubMed          Journal:  Trends Parasitol        ISSN: 1471-4922


  76 in total

1.  Ivermectin disrupts the function of the excretory-secretory apparatus in microfilariae of Brugia malayi.

Authors:  Yovany Moreno; Joseph F Nabhan; Jonathan Solomon; Charles D Mackenzie; Timothy G Geary
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

2.  Subunit stoichiometry and arrangement in a heteromeric glutamate-gated chloride channel.

Authors:  Nurit Degani-Katzav; Revital Gortler; Lilach Gorodetzki; Yoav Paas
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-20       Impact factor: 11.205

Review 3.  Control of nematode parasites with agents acting on neuro-musculature systems: lessons for neuropeptide ligand discovery.

Authors:  Richard J Martin; Alan P Robertson
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

4.  Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug.

Authors:  Eloise Mastrangelo; Margherita Pezzullo; Tine De Burghgraeve; Suzanne Kaptein; Boris Pastorino; Kai Dallmeier; Xavier de Lamballerie; Johan Neyts; Alicia M Hanson; David N Frick; Martino Bolognesi; Mario Milani
Journal:  J Antimicrob Chemother       Date:  2012-04-25       Impact factor: 5.790

Review 5.  Implication of the purinergic system in alcohol use disorders.

Authors:  Liana Asatryan; Hyung W Nam; Moonnoh R Lee; Mahesh M Thakkar; M Saeed Dar; Daryl L Davies; Doo-Sup Choi
Journal:  Alcohol Clin Exp Res       Date:  2011-01-11       Impact factor: 3.455

6.  Acquired Tolerance to Ivermectin and Moxidectin after Drug Selection Pressure in the Nematode Caenorhabditis elegans.

Authors:  Cécile Ménez; Mélanie Alberich; Dalia Kansoh; Alexandra Blanchard; Anne Lespine
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

7.  [Disseminated infiltrated cutaneous pruritis].

Authors:  H Stanisz; C Pföhler; T Vogt; C S L Müller
Journal:  Hautarzt       Date:  2012-03       Impact factor: 0.751

8.  A Pilot Study of the Safety and Initial Efficacy of Ivermectin for the Treatment of Alcohol Use Disorder.

Authors:  Daniel J O Roche; Megan M Yardley; Katy F Lunny; Stan G Louie; Daryl L Davies; Karen Miotto; Lara A Ray
Journal:  Alcohol Clin Exp Res       Date:  2016-04-18       Impact factor: 3.455

9.  Therapeutic efficacy of poly (lactic-co-glycolic acid) nanoparticles encapsulated ivermectin (nano-ivermectin) against brugian filariasis in experimental rodent model.

Authors:  Mohammad Ali; Mohammad Afzal; Meenakshi Verma; Shailja Misra Bhattacharya; F J Ahmad; Mohammad Samim; M Z Abidin; A K Dinda
Journal:  Parasitol Res       Date:  2013-12-24       Impact factor: 2.289

10.  New WS9326A congeners from Streptomyces sp. 9078 inhibiting Brugia malayi asparaginyl-tRNA synthetase.

Authors:  Zhiguo Yu; Sanja Vodanovic-Jankovic; Michael Kron; Ben Shen
Journal:  Org Lett       Date:  2012-09-12       Impact factor: 6.005

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.